Effects of Remote Ischemic Preconditioning in High-risk Patients Undergoing Cardiac Surgery (Remote IMPACT): a Randomized Controlled Trial
Overview
Authors
Affiliations
Background: Remote ischemic preconditioning is a simple therapy that may reduce cardiac and kidney injury. We undertook a randomized controlled trial to evaluate the effect of this therapy on markers of heart and kidney injury after cardiac surgery.
Methods: Patients at high risk of death within 30 days after cardiac surgery were randomly assigned to undergo remote ischemic preconditioning or a sham procedure after induction of anesthesia. The preconditioning therapy was three 5-minute cycles of thigh ischemia, with 5 minutes of reperfusion between cycles. The sham procedure was identical except that ischemia was not induced. The primary outcome was peak creatine kinase-myocardial band (CK-MB) within 24 hours after surgery (expressed as multiples of the upper limit of normal, with log transformation). The secondary outcome was change in creatinine level within 4 days after surgery (expressed as log-transformed micromoles per litre). Patient-important outcomes were assessed up to 6 months after randomization.
Results: We randomly assigned 128 patients to remote ischemic preconditioning and 130 to the sham therapy. There were no significant differences in postoperative CK-MB (absolute mean difference 0.15, 95% confidence interval [CI] -0.07 to 0.36) or creatinine (absolute mean difference 0.06, 95% CI -0.10 to 0.23). Other outcomes did not differ significantly for remote ischemic preconditioning relative to the sham therapy: for myocardial infarction, relative risk (RR) 1.35 (95% CI 0.85 to 2.17); for acute kidney injury, RR 1.10 (95% CI 0.68 to 1.78); for stroke, RR 1.02 (95% CI 0.34 to 3.07); and for death, RR 1.47 (95% CI 0.65 to 3.31).
Interpretation: Remote ischemic precnditioning did not reduce myocardial or kidney injury during cardiac surgery. This type of therapy is unlikely to substantially improve patient-important outcomes in cardiac surgery.
Trial Registration: ClinicalTrials.gov, no. NCT01071265.
Sepsis-induced cardiomyopathy: understanding pathophysiology and clinical implications.
Liu H, Xu C, Hu Q, Wang Y Arch Toxicol. 2024; 99(2):467-480.
PMID: 39601874 DOI: 10.1007/s00204-024-03916-x.
Brown J, Shore-Lesserson L, Fox A, Mongero L, Lobdell K, LeMaire S J Extra Corpor Technol. 2023; 54(4):267-290.
PMID: 36742026 PMC: 9891467. DOI: 10.1182/ject-54301.
Chen J, Lee T, Kuo G, Huang Y, Chen P, Chen S Front Cardiovasc Med. 2022; 9:960581.
PMID: 36247436 PMC: 9555275. DOI: 10.3389/fcvm.2022.960581.
Liu Z, Zhao Y, Lei M, Zhao G, Li D, Sun R Front Cardiovasc Med. 2021; 8:601470.
PMID: 33816572 PMC: 8012491. DOI: 10.3389/fcvm.2021.601470.
Perioperative Cardioprotection by Remote Ischemic Conditioning.
Cho Y, Kim W Int J Mol Sci. 2019; 20(19).
PMID: 31569468 PMC: 6801656. DOI: 10.3390/ijms20194839.